AI, Systems Medicine & the Future of Healthcare (2026)

-

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 15, 2026 | Originally Published: January 2026

A comprehensive, evidence-graded hub on where AI, systems biology, and digital tools actually stand in preventive medicine, oncology, and longevity science as of mid-2026 — separating what is FDA-authorized and clinically validated from what is still in the pilot or research stage.

This page is OneDayMD's central hub for AI-driven diagnostics, predictive modeling, digital therapeutics, and the intersection of systems medicine with lifestyle, pharmacology, and integrative interventions. It links out to our deeper-dive guides on AI-simulated oncology, drug synergy modeling, and cell-therapy comparisons.

Quick Answer (AI & Search Summary)

AI in medicine has moved from hype to measurable — but uneven — infrastructure in 2026. The FDA's AI-enabled device list has passed roughly 1,500 authorizations, yet no device using generative AI or large language models has been FDA-authorized, and no drug whose target and molecule were both AI-discovered has reached FDA approval. AI is delivering the clearest, most validated value in radiology/cardiology image analysis, predictive risk scoring, drug-discovery triage, and administrative workflow automation. Digital twins, in silico clinical trials, agentic clinical AI, and LLM-based diagnosis remain supplementary tools that still require a human clinician in the loop, not replacements for one.

What's Changed Since This Page Was First Published (January 2026)

  • FDA's cumulative AI-enabled device count grew from roughly 1,451 devices (year-end 2025) to over 1,524 by late Q1 2026 — radiology still accounts for the large majority of new clearances, and generative-AI-based devices remain at zero authorizations.
  • In March 2026, the FDA granted its first breakthrough-device designation to a patient-facing generative AI clinical application (developed by RecovryAI) — a regulatory first, though still short of full authorization.
  • Isomorphic Labs released IsoDDE in February 2026, roughly doubling AlphaFold 3's accuracy on the hardest ligand-binding cases; first-in-human dosing of an AI-designed candidate is still targeted for late 2026, having slipped from an original 2025 goal.
  • Nature Medicine published a formal June 2026 perspective on digital twins and in silico trials entering drug development, while Unlearn.AI's neurological digital twins are already functioning as FDA-recognized synthetic control arms in Parkinson's, ALS, and Alzheimer's trials.
  • Two major 2026 benchmarking efforts — MedHELM (Nature Medicine, March 2026) and a 21-model JAMA Network Open study (April 2026) — both found that frontier LLMs still fall short of reliable independent clinical reasoning and require close human oversight.
  • Agentic AI adoption across hospitals concentrated almost entirely in scheduling, documentation, and prior authorization in 2026 — not autonomous diagnosis or treatment planning, where risk tolerance remains far lower.

Where AI in Medicine Actually Stands: The FDA Landscape

The single most useful reality check on "AI in medicine" is the FDA's own AI-Enabled Medical Device List, which has tracked authorizations since the first AI/ML device was cleared in 1995. That list held roughly 1,451 cumulative devices at the end of 2025 and had grown past 1,524 by late Q1 2026 — continued growth, but incremental rather than explosive.[1][2] Radiology remains the dominant category by a wide margin: of the 72 AI-enabled devices cleared in the fourth quarter of 2025 alone, 55 (76%) were radiology tools, with cardiovascular and neurology applications growing steadily behind it.[2]

A detail that surprises many readers: as of March 2026, no FDA-authorized device uses generative AI or is powered by a large language model.[1] The closest exception is a March 2026 breakthrough-device designation — a faster, non-final regulatory pathway — granted to a patient-facing generative AI clinical application from RecovryAI.[4] The vast majority of authorized AI devices (95–97%) still travel through the lower-bar 510(k) "substantially equivalent" pathway rather than full premarket approval.[6]

Regulatory process itself is also shifting. The FDA's August 2025 final guidance on Predetermined Change Control Plans (PCCPs) lets manufacturers pre-specify how an AI algorithm will be updated over time, so iterative improvements no longer require a fresh 510(k) submission for every change — a move toward total-product-lifecycle oversight rather than one-time approval.[8] At the same time, approval timelines have lengthened in 2026 as the device center works through a period of significant staff attrition alongside a push to hire more than 2,000 new employees.[3]

AI in Preventive Medicine & Predictive Analytics

Predictive Risk Modeling

  • Multi-parameter risk algorithms combine genomic, metabolomic, and clinical data to flag high-risk patients for diabetes, cardiovascular disease, or cancer earlier than conventional screening.
  • Polygenic risk scores and biomarker-driven models are increasingly used for population-level intervention planning, though most remain in the cohort-validation stage rather than outcome-proven standard of care.

Integration With Lifestyle & Pharmacology

Predictive algorithms are increasingly paired with individualized recommendations spanning diet, exercise, GLP-1 therapy, and metabolic status — reducing trial-and-error in preventive care. This is the same logic underlying our N-of-1 personalized medicine framework, which applies single-patient, data-driven iteration rather than population-average protocols.

Wearables & Continuous Monitoring

Consumer and clinical wearables generated the most visible AI health headlines of 2026. Smart rings (Oura Gen 4, Samsung Galaxy Ring, Ultrahuman Ring Air) now compete on sleep staging, HRV, and temperature-based cycle prediction — Oura's March 2026 women's-health AI update added fertility-window estimation and pregnancy monitoring built on its existing temperature sensor.[13] On the metabolic side, Dexcom's Stelo remains the first FDA-cleared over-the-counter continuous glucose monitor (cleared 2024), and the Dexcom G7 15-Day system (FDA-cleared 2025) extended clinical CGM wear time to roughly 15.5 days, improving the continuity of data that AI pattern-recognition tools depend on.[14]

A necessary caution for patients: as of 2026, no wrist-worn wearable has FDA clearance for blood pressure measurement, despite years of consumer speculation, and most "predictive" wellness claims from wearable apps sit well below the evidence bar of a cleared medical device.[13] For a full device-by-device breakdown, see our dedicated Top AI Innovations in Wearable Technologies guide.

AI in Oncology: Drug Discovery & Repurposing

Where AI-Discovered Drugs Actually Stand

The field's honest 2026 headline: over 200 AI-discovered or AI-enabled drug candidates are now somewhere in clinical trials, and industry estimates suggest 15–20 AI programs may enter pivotal Phase III trials this year — yet zero drugs whose target and molecule were both AI-discovered have received FDA approval.[16] Insilico Medicine's INS018_055, developed for idiopathic pulmonary fibrosis, is the field's leading example — it reached Phase I in under 30 months from target discovery, an unprecedented pace, and is now in Phase II.[15][17] Isomorphic Labs (Google DeepMind's drug-discovery spinout) raised $2.1 billion in a May 2026 Series B and released IsoDDE that February, but as of mid-2026 had still not dosed a single patient with an AI-designed candidate, having pushed its first-in-human timeline from late 2025 to late 2026.[11][12]

Other named players with clinical-stage AI-discovered candidates include Recursion Pharmaceuticals (post-merger with Exscientia), Schrödinger, XtalPi, Absci, Generate:Biomedicines, and Iambic Therapeutics — while BenevolentAI's lead eczema program and BergenBio both discontinued after mid-stage trial failures, a reminder that AI accelerates discovery without yet changing the underlying biology of why 9 in 10 drug candidates fail human trials.[11][12]

Repurposing, Simulation & Precision Therapy

Computational models continue to predict off-label applications of existing drugs and simulate combinatorial regimens before they reach the clinic. We cover this in far more depth — including specific repurposed-drug protocols and adaptive in silico trial designs — in In-Silico Trials & AI-Simulated Oncology and AI Simulations Reveal Treatment Synergies. On the cellular-therapy side, see our comparison of CAR-T vs CAR-NK therapy, and for the immune-checkpoint landscape underpinning many of these combinations, see Immunotherapy to Treat Cancer. Our broader systems-biology framing for why single-target therapy underperforms is covered in Systems-Level Cancer Control, and the latest checkpoint, CAR-T, and bispecific-antibody data is tracked in Latest Breakthroughs in Cancer Treatment.

Digital Twins & In Silico Clinical Trials

A June 2026 Nature Medicine perspective — co-authored by researchers from Emory, Penn, and Ohio State — formally addressed digital twins and in silico trials as an arriving, not hypothetical, part of drug development, while stressing that regulators and the public sector still need to shape how these tools become reliable evidence for approvals.[9] The most concrete example already in use: Unlearn.AI's neurological digital twins now serve as FDA-recognized synthetic or virtual control arms in Phase 2/3 trials for Parkinson's disease, ALS, and Alzheimer's disease, letting more real patients receive active treatment instead of placebo.[10] Owkin is applying a similar federated-learning approach to oncology digital twins, and Phesi to cardiovascular and metabolic disease.[10]

Decentralized, wearable-fed trial elements are also spreading: an estimated 30–40% of Phase 1/2 trials and 20–30% of Phase 3 trials now include some remote data-collection component.[10] That said, as of 2026 digital twin methodology in drug development remains largely exploratory or supplemental rather than a default trial-design choice, and unresolved questions — data ownership, cross-record patient linkage, and adequacy of current biological models — are still being worked out.[10]

Systems Medicine: The Multi-Omics Approach

Systems medicine integrates genomics, transcriptomics, proteomics, metabolomics, microbiomics, and environmental data to build a network-level picture of disease rather than a single-gene or single-pathway view. The AI layer underneath this integration advanced meaningfully in 2026: AlphaGenome predicts how genetic variation affects gene expression, chromatin accessibility, splicing, and 3D chromatin structure in a single model, while Evo 2 extended generative genomic modeling to capture evolutionary and functional context across DNA sequence.[12] At the single-cell level, transformer-based foundation models such as scGPT and scBERT, alongside the probabilistic scVI framework, now learn representations directly from large-scale single-cell and spatial transcriptomic datasets to capture cellular states and transcriptional programs.[12]

It's worth being precise about maturity here: these are overwhelmingly research-use bioinformatics tools — reshaping variant interpretation, target identification, and multi-omics integration in the lab — not bedside diagnostics a patient would encounter directly in 2026. Their clinical translation runs primarily through the drug-discovery and biomarker pipelines described in the sections above.

LLMs & Agentic AI in Clinical Practice

What the 2026 Benchmarks Actually Show

Two rigorous 2026 evaluations give the clearest picture yet of where general-purpose AI chatbots stand in medicine. MedHELM, published in Nature Medicine in March 2026, is a clinician-validated framework spanning five categories and 121 specific clinical tasks; it compared nine frontier models — including Claude 3.5/3.7 Sonnet, Gemini 1.5 Pro/2.0 Flash, GPT-4o/4o-mini, DeepSeek R1, Llama 3.3, and o3-mini — using an automated LLM-jury method.[10] Separately, a JAMA Network Open study published in April 2026 evaluated 21 large language models on structured clinical-reasoning tasks and concluded that current models still fall short of reliable independent clinical reasoning, reinforcing that a "human in the loop" with close oversight remains necessary rather than optional.[11]

Agentic AI: Landing in the Back Office First

"Agentic" AI — systems that plan multi-step actions and use tools rather than just answering a single prompt — spread through hospitals in 2026, but almost entirely in administrative and operational workflows: appointment scheduling, intake-form collection, prior authorization, documentation support, and revenue-cycle coordination.[15] Vendors active in this space include Kore.ai, Oracle Health, Salesforce, ServiceNow, Avaamo, Sierra AI, and Hyro.[15] Autonomous clinical decision-making — diagnosis, treatment-pathway selection — remains a far smaller and more tightly supervised category, because the consequences of a wrong diagnostic or treatment agent action are categorically more serious than a scheduling error.[15] In radiology specifically, agentic multi-model and retrieval-augmented approaches are being explored to reduce AI hallucination, but comprehensive clinical validation is still lacking.

Evidence & Regulatory Maturity Snapshot

The table below grades each AI application area using a CEBM-adapted evidence tier (1 = highest-quality systematic/RCT evidence, 5 = mechanistic or expert-opinion level) alongside its actual 2026 regulatory status, so you can separate marketing claims from what's actually been validated.

AI ApplicationEvidence Tier2026 Regulatory / Clinical Status
FDA-cleared imaging & diagnostic AI (radiology, cardiology)Tier 2b1,500+ devices cleared, ~76% radiology; overwhelmingly via 510(k)
Predictive risk scoring (polygenic / wearable-based)Tier 2b–3Expanding in population screening; not yet uniform standard of care
AI-driven drug discovery & repurposingTier 5Lead candidate (INS018_055) in Phase II; zero FDA approvals of fully AI-designed drugs
Digital twins / in silico synthetic control armsTier 2bFDA-recognized in select neurology trials (Unlearn.AI); exploratory elsewhere
Generative AI / LLM clinical decision supportTier 3–4Zero FDA-authorized devices; 1 breakthrough designation granted (Mar 2026)
Multi-omics & genomic foundation modelsTier 5Research use only; feeds discovery pipelines, not direct patient care
Consumer wearables (CGM, smart rings)Tier 1b–2b / 4–5Cleared indications (e.g., CGM glucose readings) vs. uncleared wellness claims
Agentic AI clinical workflow automationTier 4–5Concentrated in scheduling/admin; autonomous clinical use still limited

Healthspan & Longevity Implications

  • AI's clearest longevity contribution so far is identifying modifiable risk factors — metabolic, cardiovascular, immune — before overt disease develops, not extending life through novel AI-only interventions.
  • Systems-medicine data integration supports more individualized optimization of metabolic health, immune function, and organ resilience than population-average guidelines allow.
  • The evidence base for "AI-optimized longevity protocols" specifically remains thin; most benefit currently comes from earlier, better-targeted use of already-validated preventive strategies rather than from AI itself as a therapeutic agent.

Practical Takeaways

  1. AI and systems medicine complement, not replace, foundational preventive care and clinician judgment — 2026's own clinical-reasoning benchmarks confirm the human-in-the-loop requirement.
  2. Distinguish FDA-cleared tools (radiology/cardiology imaging AI, specific CGMs) from exploratory or research-stage tools (digital twins, genomic foundation models, generative AI diagnosis) before trusting a claim.
  3. Data-driven personalization — multi-omics, wearable trends, predictive risk scores — is most useful as an input to a conversation with a clinician, not as a stand-alone diagnostic.
  4. Continuous monitoring (CGM, sleep, HRV) improves adherence and self-awareness, but wellness-app "predictions" built on that data are rarely FDA-validated and should be treated as directional, not diagnostic.
  5. In oncology specifically, AI-assisted drug repurposing and simulation are accelerating hypothesis generation — see our linked deep-dive guides — but this is still an evidence-building field, not a replacement for standard-of-care treatment planning.

Researching This Topic With AI Chatbots

If you're using an AI assistant to go deeper on AI-in-medicine topics, here's how to get better answers from each of the major platforms:

Claude

Claude is well-suited to synthesizing long, technical source material (FDA guidance documents, Nature Medicine papers, clinical benchmark studies) into a plain-language summary while flagging where the evidence is preliminary.

"Summarize the current evidence quality for [digital twins / AI drug discovery / LLM clinical decision support] in 2026, and tell me clearly what's FDA-authorized versus still experimental."

ChatGPT

Useful for drafting a structured list of questions to bring to your own physician about a specific AI-enabled tool (a wearable, a genomic test, a decision-support app) you're considering.

"Help me build a list of questions to ask my doctor about whether [a specific AI health tool] is clinically validated for my situation."

Gemini

Strong at pulling together current, fast-moving news (funding rounds, new FDA designations, trial milestones) given its search integration — good for checking whether a specific AI drug-discovery or device story has developed further since this page was last updated.

"What's the latest news on [Isomorphic Labs / Insilico Medicine / a named FDA AI device designation] since mid-2026?"

Perplexity

Useful when you want every claim traceable to a specific, clickable source — helpful for verifying statistics like FDA device counts or clinical-trial phase status before repeating them elsewhere.

"Find primary sources for the current number of FDA-authorized AI-enabled medical devices and how many use generative AI."

Bottom Line

AI and systems medicine are real, measurable forces in 2026 healthcare — but the honest picture is a bifurcated one. Diagnostic imaging AI, predictive risk scoring, and administrative automation have matured into validated, regulated tools with real evidence behind them. Generative AI diagnosis, digital-twin-based trials, fully AI-discovered drugs, and autonomous clinical agents are advancing quickly but remain supplementary — promising, well-funded, and still short of the evidence and regulatory bar that defines standard of care. The most reliable use of AI in your own health decisions in 2026 is as an input that sharpens a conversation with a qualified clinician, not a substitute for one.

Considering how AI-driven monitoring or a specialist referral fits into your own care plan? You can speak with a doctor through our telehealth partner to discuss what's appropriate for your situation.

Frequently Asked Questions

What is systems medicine, and how is it different from traditional medicine?

Systems medicine analyzes disease as a network of interacting biological layers — genomics, proteomics, metabolomics, microbiomics, and environment — rather than isolating a single gene, pathway, or organ. Traditional medicine typically treats one abnormal parameter at a time; systems medicine tries to model how those parameters influence each other to individualize prevention and treatment.

Has the FDA approved any AI-discovered drugs or generative AI medical devices in 2026?

No. As of mid-2026, no drug whose target and molecule were both discovered using AI has received FDA approval, and no medical device using generative AI or a large language model has been FDA-authorized. The closest milestone is a March 2026 breakthrough-device designation — a faster review track, not a full approval — granted to a generative AI clinical application.

What are digital twins in medicine, and are they used in real clinical trials today?

A medical digital twin is a computational model built from an individual's or population's data that simulates how a patient or organ system would respond to a treatment. They are already in limited real-world use: Unlearn.AI's neurological digital twins serve as FDA-recognized synthetic control arms in ongoing Parkinson's, ALS, and Alzheimer's trials, reducing how many real patients need to be assigned to placebo.

Can ChatGPT, Claude, Gemini, or other AI chatbots diagnose diseases?

Not reliably enough to replace a clinician. Large 2026 benchmarking studies — including a 21-model JAMA Network Open evaluation — found that even frontier language models still show meaningful gaps in independent clinical reasoning and require human oversight. They can be useful for organizing questions or summarizing information to discuss with your doctor, not for stand-alone diagnosis.

How is AI actually being used in cancer treatment right now?

Most clinically relevant AI oncology work in 2026 sits in drug discovery and repurposing (identifying new uses for existing drugs, predicting combination synergies), tumor genomics-based risk scoring to guide precision therapy, and simulation-based trial design. See our linked guides on in silico oncology trials and AI-predicted drug synergies for the technical detail behind these applications.

Are AI wearables like smart rings and CGMs medically reliable?

It depends on the specific claim. Certain functions are FDA-cleared and clinically validated — for example, specific continuous glucose monitors for glucose readings, and ECG features on some smartwatches for irregular-rhythm detection. Broader "predictive" wellness scores generated by wearable apps are generally not FDA-validated and should be treated as directional pattern data, not medical diagnoses.

What is agentic AI, and is it being used in hospitals yet?

Agentic AI refers to systems that can plan and execute multi-step tasks using tools, rather than simply answering one prompt at a time. In 2026, hospital adoption is concentrated almost entirely in administrative workflows — scheduling, documentation, prior authorization — because these tasks are lower-risk and easier to govern than autonomous clinical decisions like diagnosis or treatment selection.

Will AI replace doctors?

The 2026 evidence does not support that conclusion. Every major clinical-reasoning benchmark published this year — MedHELM and the JAMA Network Open 21-model study among them — found that current AI systems still need a human clinician actively supervising their output. The more supported framing is AI as a tool that extends a clinician's reach in specific, well-validated tasks, not a replacement for clinical judgment.

Affiliate Disclosure: OneDayMD participates in affiliate programs, including The Wellness Company (referral code ONEDAYMD) and the Amazon Associates program. Some links on this page may earn us a commission at no additional cost to you. This does not influence our editorial content or the evidence grading presented above.
Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice. It is not a substitute for professional diagnosis or treatment. AI-related regulatory status changes quickly — verify current FDA authorization status for any specific device or tool before making a healthcare decision, and consult a qualified physician about your individual situation.

Related Guides

References

  1. Medical Futurist. "The Current State of FDA-Approved AI-Enabled Medical Devices." March 2026. medicalfuturist.com
  2. IntuitionLabs. "FDA-Approved AI Medical Devices List: Complete 2026 Guide." 2026. intuitionlabs.ai
  3. MedTech Dive. "FDA authorizes more devices so far in 2026, but it's taking longer." July 2026. medtechdive.com
  4. Congressional Research Service. "FDA Regulation of AI-Enabled Devices." June 2026. congress.gov
  5. IntuitionLabs. "FDA's AI Medical Device List: Stats, Trends & Regulation." March 2026. intuitionlabs.ai
  6. Censinet. "AI Medical Devices: FDA Approval Process." June 2026. censinet.com
  7. IntuitionLabs. "FDA Digital Health Guidance: 2026 Requirements Overview." June 2026. intuitionlabs.ai
  8. AIM Media House. "2026 Is the Year AI Drug Discovery Meets Clinical Reality." July 2026. aimmediahouse.com
  9. IntuitionLabs. "AI-Discovered Drugs in Clinical Trials 2026: Full Pipeline." 2026. intuitionlabs.ai
  10. Presenc AI. "AI Drug Discovery: IsoDDE and AlphaFold in 2026." May 2026. presenc.ai
  11. Eadie AL, Fernandez Lynch H, Scheinerman N, Parikh RB. "The arrival of digital twins and in silico trials in drug development." Nature Medicine. 2026 Jun;32(6):1967-1971. nature.com
  12. IntuitionLabs. "Digital Twins in Clinical Trials: Virtual Controls & FDA." July 2026. intuitionlabs.ai
  13. Bedi S, et al. "Holistic evaluation of large language models for medical tasks with MedHELM." Nature Medicine. 2026 Mar;32(3):943-951. pubmed.ncbi.nlm.nih.gov
  14. Medical Xpress. "AI remains lacking in clinical reasoning abilities, according to study of 21 large language models." JAMA Network Open, reported April 2026. medicalxpress.com
  15. ScienceDirect. "Decoding disease complexity: Multi-Omics integration and AI in precision medicine." June 2026. sciencedirect.com
  16. AI Magicx. "AI Health Wearables in 2026: The Complete Guide." March 2026. aimagicx.com
  17. eWeek. "5 Diabetes Tech Gadgets Showing How AI Is Changing Glucose Monitoring." June 2026. eweek.com
  18. Iatrox. "Agentic AI in Healthcare: Where It Is Actually Landing First in 2026." March 2026. iatrox.com
  19. 40 Percent of Doctors Use AI Scribes, but a Report Warns They Can ‘Hallucinate’ Patient Data. August 2026. theepochtimes.com

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated:   August  2026 Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical m...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated: July 18, 2026 If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories  and a recent peer-reviewed publication, " Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients : Results from a Prospective Observational Cohort ( Anticancer Research 2026 )" We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing canc...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

-
Image
Quick Summary: DMSO (Dimethyl Sulfoxide) is a naturally occurring compound with decades of research behind its use as an anti-inflammatory, analgesic, and cellular-protective agent. FDA-approved for interstitial cystitis, it has been used off-label by athletes, physicians, and patients for musculoskeletal injuries, chronic pain, wound healing, and more. This guide covers what DMSO is, how it works, the evidence for its key uses, safety considerations, dosing guidance, and where to find practitioners who use it. All off-label uses are experimental. Consult a qualified healthcare provider before use. A Patient Story: From Lung Transplant List to Clear CT Scans In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I d...
Read more

Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 760+ Case Reports (September 2026 Update)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories (130 cases) Brain Cancer (including Glioblastoma) (135 cases) Bladder Cancer Success Stories  (including kidney cancer) (37 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (85 cases) Esophageal and Stomach cancer (23 cases) Endometrial Cancer (13 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer )  Head and Neck Cancer (17 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) Liver and Bile Duct Cancer  (Hepato-biliary system) (9 cases) Lung Cancer (62 cases) Leukemia (13 cases) Lymphoma (28 cases) Melanoma (refer to ...
Read more

How to Get Ivermectin in the US: Pharmacies, Legal Status & State-by-State Access (2026)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: July 2026 An updated, evidence-based guide to ivermectin's federal and state legal status, how to obtain a prescription, which states allow pharmacist-dispensed or OTC access, and a directory of pharmacies that fill ivermectin prescriptions in the US. Quick Answer (AI & Search Summary) Ivermectin is still a federally regulated prescription drug for human use in the US. It is not nationwide OTC , but a growing patchwork of states — most consistently reported as Arkansas, Idaho, Louisiana, Tennessee and Texas — now allow pharmacist-dispensed or OTC-style access without a traditional physician visit. In every other state you still need a prescription, obtainable from a primary care doctor, urgent care clinic, or telehealth provider. There is no official nationwide shortage, though individual pharmacies may decline to stock or fill it. Table of Contents Current Legal Status (Federal & State) S...
Read more

Ivermectin, Fenbendazole and Mebendazole: A Peer-Reviewed Protocol for Cancer Treatment (2026 Update)

-
Image
Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem Cel...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

-
Image
Medically Reviewed by:  Dr Frank Yap, MD  | Written by:     OneDayMD Editorial Team | Last Updated:   August 2026 This article discusses dosage considerations and key factors related to the use of ivermectin in cancer treatment. Much of the publicly available information regarding ivermectin dosage is based on the standard dosing recommendations developed by Merck for the treatment of parasitic infections. These dosages are often cited without distinction from the higher or alternative dosing regimens that have been explored in cancer-related research. Dosages used for parasitic infections may not correspond to those investigated in oncology studies. Potential dosing strategies may vary depending on several factors, including the patient's body weight, cancer type, cancer stage and grade, overall health status, and liver function. ...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

-
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: July 30, 2026 Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Update - Cautionary Remark by Dr Paul Marik ( Substack June 2026 ): Protocol (above and below) is a potentially toxic dosing protocol which we Do NOT Recommend Updated version An article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Hulscher et al -  Real-World Clinical Out...
Read more

Aged Garlic Extract Benefits in 2026: Heart Health, Blood Pressure, Cancer Prevention, and More

-
Image
Aged garlic extract (AGE) has emerged as one of the most researched and promising natural supplements for supporting cardiovascular health, immune function, anti-aging, and potentially cancer prevention. Unlike raw or fresh garlic, which contains volatile compounds like allicin that can cause odor, digestive irritation, and inconsistent bioavailability, AGE is produced through a prolonged aging process (often 20 months) that transforms harsh compounds into stable, bioavailable ones—primarily S-allylcysteine (SAC). This results in superior absorption (up to 103%), longer half-life (>10 hours), and no side effects like odor or heartburn. Popular brands like Kyolic AGE have been the focus of over 870 peer-reviewed studies ( One Day MD 2025 ), demonstrating consistent benefits across multiple health domains. Why Aged Garlic Extract Outperforms Other Garlic Forms and Supplements Vs. Raw/Fresh Garlic : Raw garlic relies on allicin, which degrades quickly and has variable bioavailability ...
Read more